Silence Therapeutics is a leading RNA therapeutics company. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Listed on London’s AIM since 2005 (AIM: SLN), and with operations in London and Berlin, Silence is one of very few listed companies globally with human validated RNA delivery systems. Its AtuRNAi® technology is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. It has been used in three Phase 2 clinical trials, two awaiting results. Delivery capability is key for the next stage in genetic medicine, targeting disease right at the cause. Silence has an expanding early stage pipeline and collaborates with world leading research institutions to develop the most promising drug candidates. For more information, visit us at www.silence-therapeutics.com, or follow us on Twitter - @SilenceTheraPlc
Show more
Type
Public
HQ
London, GB
Founded
1999
Size (employees)
59 (est)+6%
Silence Therapeutics was founded in 1999 and is headquartered in London, GB
Report incorrect company information

Silence Therapeutics Office Locations

Silence Therapeutics has an office in London
London, GB (HQ)
72 Hammersmith Rd
Show all (1)
Report incorrect company information

Silence Therapeutics Financials and Metrics

Silence Therapeutics Financials

Silence Therapeutics's revenue was reported to be £16 k in FY, 2017
GBP

Revenue (FY, 2017)

16 k

Net income (FY, 2017)

(1.6 m)

EBITDA (FY, 2017)

(14.3 m)

EBIT (FY, 2017)

(14.4 m)

Market capitalization (27-Oct-2017)

157.9 m

Closing share price (27-Oct-2017)

2.4

Cash (31-Dec-2017)

42.7 m
Silence Therapeutics's current market capitalization is £157.9 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

4 m2.2 m1.7 m2.4 m693.6 k163 k117 k15 k770 k16 k

Revenue growth, %

(87%)

Cost of goods sold

4.8 m6.7 m5.1 m5.8 m3.4 m3.4 m

Gross profit

(796 k)(4.5 m)(3.4 m)(3.5 m)(2.7 m)(3.2 m)
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.2 m3.4 m1.1 m3.6 m3.7 m8.9 m15.9 m16.9 m51.9 m39 m42.7 m

Accounts Receivable

201 k692 k164.9 k598 k35.9 k2 k375 k1.6 m810 k

Inventories

27.4 k

Current Assets

11.6 m4.4 m1.8 m4.4 m3.9 m9.1 m21.3 m22.2 m53.6 m42 m45.5 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(5.1 m)(7.4 m)(7.5 m)(8.8 m)(5.7 m)(26.3 m)(9 m)(11.1 m)(6.6 m)(8.4 m)(1.6 m)

Cash From Operating Activities

3.8 m(7 m)(4.6 m)(10.6 m)(5.1 m)(4.9 m)(6.8 m)(9.5 m)(8.3 m)(10.1 m)(9.6 m)

Cash From Financing Activities

5.2 m3.8 k2.7 m12.4 m5.5 m10.2 m18.8 m10.8 m39.2 m(101 k)48 k

Net Change in Cash

1.4 m(7 m)(2.2 m)2.4 m165.1 k5.2 m6.9 m1.2 m35.2 m(14.8 m)3.5 m
GBPY, 2017

Revenue/Employee

278.3

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information